secwatch.observer — SEC 8-K summary
======================================

Issuer:     Calidi Biotherapeutics, Inc. (CLDI)
CIK:        0001855485
Form:       8-K
Filed at:   2026-06-18T21:00:32+00:00
Accession:  0001493152-26-029374
Event type: other_material
Sentiment:  neutral
Materiality: 0.60
Item codes: 5.07
LLM model:  deepseek-v4-flash:cloud@v2

Stockholders approve reverse stock split (1:2 to 1:16) and equity plan increase to 1.95M shares
--------------------------------------------------------------------------------

- Elected Scott Leftwich as Class III director with 3.27M votes for, 1.38M withheld.
- Ratified CBIZ CPAs as independent auditor for FY2026 with 6.67M for, 304k against.
- Approved reverse stock split at ratio between 1:2 and 1:16 at Board's discretion (6.51M for).
- Approved amendment to 2023 Equity Incentive Plan, increasing authorized shares from 282,815 to 1,950,000.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1855485/000149315226029374/0001493152-26-029374-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1855485/000149315226029374/form8-k.htm
  HTML page:      https://secwatch.observer/filing/0001493152-26-029374

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer